FDA Approves Baraclude (entecavir) for Chronic Hepatitis B
29 March 2005 - Bristol-Myers Squibb
announced that the U.S. Food and Drug Administration (FDA) approved
the oral antiviral drug BARACLUDE (entecavir) for the treatment
of chronic hepatitis B infection in adults. The drug will be available
in the United States as early as April 8, 2005. Read
Full Article
Page last modified October 21, 2009
